<< Jeezus!!!!!!!!! Enough about the freakin earnings report already!!!!! Who gives a flying one???? NOBODY. >>
Sorry Dave, one last comment on the subject and then I promise to drop it. <g>
<< FUTURE earnings/burn are what count not past losses. >>
I agree. I don't think that looking at Ligand's, or any clinical stage biotech company's net income is as meaningful as looking at the quarter's funding, burn rate and pipeline activity. Ligand's recent funding has been $20 million and $30 million issue price from the Elan deal and $12.5 million from the warrant deal. That, to me, is a very significant 4th quarter impact on Ligand's ability to fund it's pipeline.
I don't care if Ligand funds it's pipeline thru revenues listed on the income statement, or from revenues listed on the balance sheet. The important thing, as you so stated, is future earnings and burn (plus stock dilution).
Some of the CPAs on this thread might have a bird, but when the 4th quarter earnings press release comes out, the first items that I will look at is "cash on hand", revenues and net loss.
Then I will peruse the report to see what Robinson has to say.
Anyway, David, have a good night, Bob |
